MX2015017489A - Supresion del picor. - Google Patents

Supresion del picor.

Info

Publication number
MX2015017489A
MX2015017489A MX2015017489A MX2015017489A MX2015017489A MX 2015017489 A MX2015017489 A MX 2015017489A MX 2015017489 A MX2015017489 A MX 2015017489A MX 2015017489 A MX2015017489 A MX 2015017489A MX 2015017489 A MX2015017489 A MX 2015017489A
Authority
MX
Mexico
Prior art keywords
itch
pruriceptor
drg neuron
specific drg
protease
Prior art date
Application number
MX2015017489A
Other languages
English (en)
Other versions
MX369006B (es
Inventor
Keith Foster
Original Assignee
Ipsen Bioinnovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd filed Critical Ipsen Bioinnovation Ltd
Publication of MX2015017489A publication Critical patent/MX2015017489A/es
Publication of MX369006B publication Critical patent/MX369006B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21072—IgA-specific serine endopeptidase (3.4.21.72)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24013—IgA-specific metalloendopeptidase (3.4.24.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La invención proporciona a polipéptido, para usarse en la supresión o tratamiento del picor, en donde el polipéptido comprende: una proteasa no citotóxica, cuya proteasa es capaz de escindir una proteína SNARE en una neurona o un pruriceptor DRG específico del picor; una Porción Dirigida (TM) que es capaz de unirse al Sitio de Unión en la neurona o un pruriceptor DRG específico del picor, cuyo Sitio de Unión es capaz de experimentar endocitosis a ser incorporada en el endosoma dentro de la neurona o un pruriceptor DRG específico del picor, y en donde tal neurona o un pruriceptor DRG específico del picor expresa tal proteína SNARE; y un dominio de translocación que es capaz de translocar la proteasa desde el interior de un endosoma, a través de la membrana endosómica y dentro del citosol de la neurona o un pruriceptor DRG específico del picor; siempre que el polipéptido no sea una molécula de neurotoxina clostridial (holotoxina).
MX2015017489A 2013-07-09 2014-07-09 Supresion del picor. MX369006B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1312295.7A GB201312295D0 (en) 2013-07-09 2013-07-09 Suppression of itch
PCT/GB2014/052101 WO2015004464A1 (en) 2013-07-09 2014-07-09 Suppression of itch

Publications (2)

Publication Number Publication Date
MX2015017489A true MX2015017489A (es) 2016-07-28
MX369006B MX369006B (es) 2019-10-24

Family

ID=49033545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017489A MX369006B (es) 2013-07-09 2014-07-09 Supresion del picor.

Country Status (14)

Country Link
US (2) US20160137999A1 (es)
EP (1) EP3019241B1 (es)
JP (2) JP6675306B2 (es)
KR (1) KR102181505B1 (es)
CN (1) CN105492074A (es)
AU (1) AU2014288956B2 (es)
CA (1) CA2915426A1 (es)
EA (1) EA201690193A1 (es)
ES (1) ES2682679T3 (es)
GB (1) GB201312295D0 (es)
MX (1) MX369006B (es)
SG (1) SG11201510578PA (es)
UA (1) UA118197C2 (es)
WO (1) WO2015004464A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
US20210277071A1 (en) 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778634B2 (en) * 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
WO2011020052A1 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
KR20120107988A (ko) * 2009-12-16 2012-10-04 알러간, 인코포레이티드 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소
JP2013521232A (ja) * 2010-02-26 2013-06-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 局所投与のためのスピロオキシインドール化合物の医薬組成物および治療剤としてのその使用
ES2610159T3 (es) * 2010-04-12 2017-04-26 Somalogic, Inc. Aptámeros para ß-NGF y su uso en el tratamiento de enfermedades y trastornos mediados por ß-NGF
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins

Also Published As

Publication number Publication date
WO2015004464A1 (en) 2015-01-15
KR20160030392A (ko) 2016-03-17
CN105492074A (zh) 2016-04-13
AU2014288956A1 (en) 2016-02-11
KR102181505B1 (ko) 2020-11-23
SG11201510578PA (en) 2016-01-28
MX369006B (es) 2019-10-24
JP2020039349A (ja) 2020-03-19
JP2016528889A (ja) 2016-09-23
EP3019241B1 (en) 2018-05-30
JP6675306B2 (ja) 2020-04-01
US20160137999A1 (en) 2016-05-19
GB201312295D0 (en) 2013-08-21
UA118197C2 (uk) 2018-12-10
ES2682679T3 (es) 2018-09-21
CA2915426A1 (en) 2015-01-15
EP3019241A1 (en) 2016-05-18
EA201690193A1 (ru) 2016-05-31
AU2014288956B2 (en) 2019-10-24
US20180298367A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
MX2020010262A (es) Manufactura de neurotoxinas de clostridium botulinum recombinantes.
MX2020007596A (es) Neurotoxinas botulinicas para escindir una proteina de receptor de union a factor sensible a n-etilmaleimida soluble (snare) no neuronal.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
EA201990229A1 (ru) Новый ботулинический нейротоксин и его производные
AU2017260389A1 (en) Chimeric neurotoxins
MX2021006714A (es) Neurotoxinas cationicas.
EP3604535A3 (en) Methods and compositions for weed control
PH12016500239A1 (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
MX348047B (es) Proteinas de fusion terapeuticas.
EA201390940A1 (ru) Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком
AU2014236990A8 (en) Gla domains as therapeutic agents
CA2899448C (en) Selective delivery molecules and methods of use
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
UA117349C2 (uk) Одноланцюговий гібридний білок та спосіб лікування, попередження або усунення болю
WO2015063747A3 (en) Peptide inhibitors of tead/yap-taz interaction
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
BR112015014727A2 (pt) composição imunogênica, uso de uma composição imunogênica, e, método para prevenir ou tratar a doença c.difficile
MX369006B (es) Supresion del picor.
WO2018136620A3 (en) Endosomal cleavable linkers
WO2013029011A3 (en) Methods and compositions comprising a c-terminal bax peptide
PE20180659A1 (es) Peptidos lipidados resistentes a proteasas
RU2015139830A (ru) Терапевтические средства для подавления остеопороза
WO2014130655A8 (en) Compositions and methods to inactivate and/or reduce production of microbial toxins

Legal Events

Date Code Title Description
FG Grant or registration